The Motley Fool

4 relentless compounding stars to buy today

Successful investing doesn’t need to be complicated.

If you have a long-term view, a huge amount of success can be had simply by sticking to the basics: buying solid, un-sexy companies at decent prices.

The growth of these companies often looks unremarkable – 6% here here, 8% there… maybe a 3% dividend – but as these businesses grow year-after-year, the incredible power of compounding will usually send the share price – and your wealth – soaring.

These types of companies are easy to overlook, but deserve to considered as a core part of an investment portfolio.

Although not technically a company I think iShares Global Consumer Staples ETF (ASX: IXI) – an exchange traded fund – is a great starting point. The fund holds some of the world’s biggest consumer brands which earn bundles of cash and can easily pass on price increases to consumers, compounding returns year, after year, after year.

Breathing device manufacturer ResMed Inc. (CHESS) (ASX: RMD) is in a similar position. The company has grown income before taxes at a compounded annual rate of 5% over the last five years and with a growing market for healthcare spending, along with regular reinvestment in research and development, the company still has a long way to go.

Like ResMed, utility software company Gentrack Group Ltd (ASX: GTK) pays out a regular, growing dividend and, with the help of a couple of acquisitions along the way, has grown EBITDA (Earnings Before Interest, Tax Depreciation and Amortization), at an annual compounded rate of 24% over the last five years. The company currently pays a nice 2.5% dividend and is targeting a long term organic EBITDA growth of 15% per year.

Finally, blood product company CSL Limited (ASX: CSL) is another company resilient to broad consumer economic cycles and an absolute compounding star. Not only does the company earn completely ridiculous returns on equity, over the last five years the company has pushed earnings per share up at a compounded 9% per year!

CSL looks more expensive relative to annual earnings, but with a history of staggering returns it’s easy to see why investors are willing to stump up a premium for the company.

NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading over 40% off its high, all while offering a fully franked dividend yield over 3%...

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

CLICK HERE FOR YOUR FREE REPORT!

Regan Pearson owns shares of GENTRACK FPO NZ.

You can follow him on Twitter @Regan_Invests.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of iShares Global Consumer Staples ETF. The Motley Fool Australia has recommended GENTRACK FPO NZ and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.